Swedish Orphan Biovitrum
Swedish Orphan Biovitrum AB, commonly known as Sobi, is a leading biopharmaceutical company headquartered in Sweden (SE). Founded in 1991, Sobi has established itself as a key player in the biotechnology industry, focusing on rare diseases and specialty care. With a strong operational presence across Europe, North America, and the Asia-Pacific region, Sobi is dedicated to developing innovative therapies that address unmet medical needs. Sobi's core product portfolio includes treatments for haemophilia, inflammation, and genetic disorders, distinguished by their commitment to patient-centric solutions and advanced biopharmaceutical technologies. The company has achieved significant milestones, including strategic partnerships and a robust pipeline of therapies, solidifying its market position as a trusted provider in the rare disease sector. Sobi continues to make strides in improving patient outcomes and enhancing the quality of life for those affected by complex health conditions.
DitchCarbon Score
How does Swedish Orphan Biovitrum's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Swedish Orphan Biovitrum's score of 59 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Swedish Orphan Biovitrum's reported carbon emissions
In 2024, Swedish Orphan Biovitrum (Sobi) reported total carbon emissions of approximately 253,133,000 kg CO2e, comprising 1,097,000 kg CO2e from Scope 1, 771,000 kg CO2e from Scope 2, and a significant 251,456,000 kg CO2e from Scope 3 emissions. This marked a slight increase in Scope 1 emissions from 1,053,000 kg CO2e in 2023, while Scope 2 emissions decreased from 815,000 kg CO2e. The total emissions for 2023 were approximately 193,109,000 kg CO2e from Scope 3, indicating a growing reliance on upstream activities. Sobi has set ambitious climate commitments, aiming for a 50% reduction in operational greenhouse gas emissions from a 2015 baseline by 2025 for both Scope 1 and Scope 2 emissions. Additionally, the company has committed to achieving net-zero emissions for its operational footprint by 2030. Furthermore, Sobi has established a near-term target to reduce absolute Scope 1 and 2 emissions by 37.8% between 2023 and 2029, with a goal that 65% of its suppliers will have science-based targets by FY2029. These initiatives reflect Sobi's commitment to sustainability and align with industry standards for climate action, demonstrating a proactive approach to reducing its carbon footprint in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 156,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | 000,000 | 00,000 | 0,000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | 922,000 | 0,000,000 | 0,000,000 | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Swedish Orphan Biovitrum is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
